NDAINJECTIONINJECTABLE
Approved
May 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
QUELICIN (succinylcholine chloride) by Pfizer is blocker. Approved for mechanical ventilation. First approved in 1953.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUELICIN (succinylcholine chloride) is a depolarizing neuromuscular blocking agent used to facilitate mechanical ventilation in anesthesia. It works by combining with cholinergic receptors at the motor end plate to produce depolarization and rapid flaccid paralysis within less than one minute, with effects lasting 4-6 minutes after single IV administration.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests contracting team sizes and shift toward cost management and market defense strategies.
Mechanism of Action
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Indications (1)
Worked on QUELICIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.